RPL17 and neoplasm: Immune checkpoint molecules such as PD-1 and CTLA-4, along with their respective inhibitors (anti-PD-1/anti-PD-L1 and anti-CTLA-4), enhance anti-tumor immunity by attenuating negative feedback mechanisms that normally restrain immune activation at checkpoint interfaces.